Crinetics Pharmaceuticals Presenting New Data from Open Label Extension Trial of Paltusotine in Acromegaly at the Society for Endocrinology BES Congress
November 08, 2021 08:00 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Nov. 08, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals to Participate in September Investor Conferences
September 07, 2021 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development, and commercialization of novel...
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
July 29, 2021 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 29, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Dosing of First Patient in Phase 3 PATHFNDR-1 Study Evaluating Oral Paltusotine for the Treatment of Acromegaly
June 28, 2021 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
- If successful, paltusotine would offer acromegaly patients a once-daily oral treatment option - SAN DIEGO, June 28, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a...
Crinetics Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 06, 2021 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
Paltusotine Phase 3 PATHFNDR program in acromegaly initiated in 2Q 2021 Phase 1 data for CRN04894 and CRN04777 expected in mid-2021 SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- Crinetics...
Crinetics Pharmaceuticals Announces Pricing of Public Offering of Common Stock
April 07, 2021 18:31 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, April 07, 2021 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Announces Phase 2 ACROBAT Edge Study with Paltusotine in Acromegaly Met Primary Endpoint
October 26, 2020 07:02 ET
|
Crinetics Pharmaceuticals, Inc.
ACROBAT Edge Results Showed Maintenance of IGF-1 Suppression with Paltusotine After Switching from Depot Somatostatin Receptor Ligand Monotherapy Paltusotine was observed to be well tolerated among...
Crinetics Pharmaceuticals Provides New Data from Paltusotine and ACTH Antagonist Development Programs at European Congress of Endocrinology
September 04, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, Sept. 04, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...
Crinetics Pharmaceuticals Reports Second Quarter 2020 Financial Results and Provides Corporate Update
August 07, 2020 07:30 ET
|
Crinetics Pharmaceuticals, Inc.
Paltusotine received Orphan Drug Designation for the treatment of acromegaly Half of the enrolled patients in the ongoing Phase 2 ACROBAT Edge clinical trial for paltusotine had completed the study...
Crinetics Pharmaceuticals Receives Orphan Drug Designation for Paltusotine for the Treatment of Acromegaly
July 08, 2020 16:05 ET
|
Crinetics Pharmaceuticals, Inc.
SAN DIEGO, July 08, 2020 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of...